The drug 9-p-D-arabinofuranosyladenine (ara-A) significantly suppressed the formation of herpes simplex virus type 1-induced syncytia in BHK-21/4 cells at concentrations as low as 0.1 ,ug/ml. Optimal activity was noted when the drug was added before initiation of viral deoxyribonucleic acid (DNA) synthesis (3.5 h postinfection). The deaminated derivative of ara-A, 9-3-D-arabinofuranosylhypoxanthine (ara-H), was at least 10 times less effective in suppressing the development of herpes simplex virus-induced syncytia. The replication ofherpes simplex virus was measured by assaying fluids and cells from infected drugtreated cultures by using a plaque production technique. Ara-A at drug levels of >10 < 32 ,ug/ml completely blocked the replication of infectious virus particles.
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Ara-H was less effective than ara-A in reducing the replication of virions. Rates of host and viral DNA synthesis were monitored by pulse labeling herpes simplex virus-infected synchronized KB cells with [3H]thymidine and subsequently separating viral from cellular DNA in CsCl density gradients. During synthetic (S) phase, ara-A or ara-H at concentrations ranging from 3.2 to 32 Lg/ml selectively inhibited viral DNA synthesis. At 3.2 ,ug of ara-A per ml, viral DNA synthesis was reduced 74% although total cellular DNA synthesis was unaffected. Increasing concentrations of ara-A produced increasing temporal delays in the maximal rate ofhost DNA synthesis. This time shift was not observed in cells treated with ara-H.
The nucleoside antibiotic 9-3-D-arabinofuranosyladenine (ara-A) was first synthesized in 1960 as a potential anticancer agent (16) . The antiviral activity of the drug was announced in 1964 by Privat de Garilhe and de Rudder, who found that ara-A had marked antiviral activity toward herpes simplex virus (HSV) and vaccinia virus (22) and that 333 ,uM ara-A completely suppressed viral replication but not the associated virus-induced cytopathogenic effect (7) . Independently, investigators at Parke, Davis and Co. observed antiviral activity directed against HSV in an antibiotic concentrate derived from a fermentation beer ofStreptomyces antibioticus. In 1967 the active component was identified as ara-A, and in 1968 the in vitro antiviral activities of this naturally occurring substance and its deaminated catabolite 9- ,-D--arabinofuranosylhypoxanthine (ara-H) were reported (18) . Subsequent studies have shown ara-A to possess broad-spectrum activity against deoxyribonucleic acid (DNA) viruses in cell culture (24) .
It has been reported (17) that HSV type 1 was more susceptible to ara-A than was HSV type 2. Other workers, however, have found that the observed variation was explainable in terms of the cell culture system used and the passage history of the virus (21) and the HSV types 1 and 2 cannot be reliably separated by type using in vitro drug susceptibility patterns (S. R. Jones, P. J. Luby, and D. McElligott, Clin. Res. 21:603, 1973) .
Hubert-Habart and Cohen noted in 1962 that ara-A inhibited DNA synthesis in a purine auxotroph of Escherichia coli (15) . Subsequent to this observation it has been suggested that ara-A or its corresponding nucleotide may inhibit DNA synthesis in eukaryotic or prokaryotic cells by (i) acting as a chain terminator (30) , (ii) inhibiting the enzyme ribonucleotide reductase (19, 31) , or (iii) inhibiting the action of DNA polymerase (10, 19) . Although biochemical studies of this nature have not been extended to virus-infected cells, it is presumed that the antiviral activity of ara-A is due to the inhibition of viral DNA synthesis.
We have previously shown (28) that ara-A selectively inhibits chromosomal but not circular DNA synthesis in a line of virus-transformed embryonic rat cells. In this communication we present experimental evidence for the antiviral activity of ara-A and its catabolite ara-H. Our findings suggest that both drugs selectively inhibit the synthesis of viral DNA.
MATERIALS AND METHODS Ara-A was provided through the courtesy of Harold E. Machamer and Robert Hodges of Parke, Davis and Co., Detroit and Ann Arbor, Mich. Ara-H was purchased from Pfanstiehl Laboratories, Inc., Waukegan, Ill. The purity of ara-H was examined chromatographically by gas-liquid and high-pressure liquid techniques. A 1.2 to 1.5% contaminant was detected which chromatographed as ara-A in both systems. [methyl-3H]thymidine was obtained from New England Nuclear Corp., Boston, Mass. HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) and Pronase were purchased from Calbiochem, La Jolla, Calif.
Serum. Extensively heated (12 h at 56 C) calf serum (Flow Laboratories, Inc., Rockville, Md.) was used in experiments involving ara-A in order to inhibit the serum-associated deamination of ara-A to ara-H. We have previously shown (26) Monolayer cultures of KB cells were grown in Eagle minimal essential medium (MEM) with either Hanks salts or Earle salts supplemented with 10% unheated calf serum. The sodium bicarbonate concentration was varied to meet the buffering capacity required. Cells were passaged according to conventional procedures by using 0.05% trypsin plus 0.02% ethylenediaminetetraacetic acid in a HEPESbuffered balanced salt solution (see ref. 27) .
Suspension cultures of KB cells were grown at 37 C in MEM with spinner salts (NaHCO3 omitted) supplemented with 10% extensively heated calf serum. The pH was maintained at 7.0 by using 10 mM HEPES. Suspension-grown KB cells had an average population doubling time of 30 h. Cells were maintained at a density of 2 x 105 to 4 x 105 cells/ml at a volume of 300 ml in hanging bar-type 500-ml spinner flasks (Bellco Glass Co., Inc., Vineland, N.J.).
To increase the likelihood of detecting bacterial and/or mixed bacterial and mycoplasmal contamination, antibiotics were never included in any tissue culture media (14) . All cell lines were screened periodically (tests performed by Microbiological Associates, Bethesda, Md.) and were found to be mycoplasma free.
Cell counts. Total cell counts were made with a Coulter counter equipped with a 100-,um orifice. Viable counts were determined by means of trypan blue dye exclusion.
Virus. The HF strain of HSV was obtained from Gary H. Cohen. High-titered virus stock preparations were prepared as follows. Nearly confluent monolayer cultures of KB cells grown in 16-or 32-oz (about 480-or 960-ml) glass bottles (Brockway Glass Co., Inc., Brockway, Pa.) containing MEM plus Hanks salts supplemented with 10% unheated calf serum and 2x arginine were infected at an input multiplicity of 5 to 10 plaque-forming units (PFU) per cell. After 24 h the cells were harvested by vigorous shaking, washed with fresh medium, and concentrated by centrifugation (5 min at 300 x g). The cell pellet was resuspended in 1/40 of the original volume of medium and sonicated for 60 s at 20 kHz in a Bronwill Sonicator (Bronwill Scientific Inc., Rochester, N.Y.) set to deliver 70 W of acoustical power through a needle probe. The preparations were clarified by centrifugation at 500 x g for 10 min to remove cell debris. The resulting supernatant fluids, which exhibited titers ranging from 3 x 108 to 1 x 109 PFU/ml, were stored at -76 C until retrieved.
Titration of virus. HSV was assayed by using monolayer cultures of BHK-21/4 cells grown in Integrid tissue culture dishes (60 by 15 mm; Falcon Plastics, Oxnard, Calif.). The cells were planted at 106 cells/dish in Ham nutrient mixture F-12 supplemented with 5% unheated fetal bovine serum. After 22 to 24 h the cells were 90% confluent and were inoculated with 0.2 ml of the virus suspension to be assayed and incubated in a humidified 3% C02-97% air atmosphere for 1 h to permit viral adsorption.
For the syncytial assay, the medium was replaced with 5 ml of F-12 medium and incubated at 37 C for an additional 22 to 24 h. After incubation, the cells were fixed in situ, stained with alum hematoxylin, and rinsed with a HEPES-buffered balanced salt solution, and syncytia were enumerated.
For plaque assays, the cells were overlaid after adsorption with 5 ml of F-12 medium containing 0.5% methocel (4,000 centipoise/s) (Dow Chemical Co., Midland, Mich.) and incubated an additional 4 days. After fixation with neutral formalin, the cells were stained with Giemsa tissue stain, Wolbach modification (Paragon C. and C. Co., Inc., Bronx, N.Y.), and macroscopic plaques were enumerated by using a Digimatic colony counter (Lab Line Instruments, Inc., Melrose Park, Ill).
Cell synchronization. Suspension cultures of KB cells were synchronized by the double-thymidine block method (5) as modified by Bello (3) . In brief, KB cells in suspension culture were treated with 2 mM thymidine for 18 to 20 h, centrifuged at 300 x g for 5 min, resuspended in fresh warm medium at 37 C to reverse the thymidine block, and then allowed to grow an additional 9 to 12 h. At 
RESULTS
Inhibition of HSV-induced syncytia by ara-A and ara-H. Table 1 compares and contrasts the effects of ara-A and ara-H on the ability of the HF strain of HSV type 1 to induce syncytia in monolayers of BHK-21/4 cells. Ara-A, when added within 6 h of the viral adsorption period, was a potent inhibitor of syncytia formation. Ara-H was approximately one-tenth as effective as ara-A, reducing syncytia formation 85% at the highest drug level tested.
Interference by ara-A with the replication of HSV. The effect of ara-A on the replication of HSV in synchronized KB cells is shown in Fig.  1A . The titer of HSV in the cells and supernatant fluid was inversely proportional to the amount of drug present. Although 10 ,g of ara-A per ml reduced the titer at 12 h by 70%, 32 ,ug/ml was required to block de novo replication of HSV virions.
Interference by ara-H with the replication of HSV. Figure 1B shows the effect of ara-H on virus production in drug-treated suspension cultures of synchronized KB cells. Ara-H was less efficient than ara-A as an inhibitor of viral replication. Low levels of ara-H had a minimal effect on the replication of HSV virions. The highest dose tested, 32 ,ug/ml, did not completely block synthesis of virus as had an equivalent concentration of ara-A, although the titer of virus at 12 h was reduced by 84%. Inhibition of DNA synthesis by ara-A in uninfected cells. The effect of ara-A on the rate of DNA synthesis in uninfected cultures of KB cells synchronized by the double-thymidine block method is illustrated in Fig. 2 . A typical burst of DNA synthetic activity in the absence of drug is shown in panel A. The maximal rate of DNA synthesis occurred at 3.5 h after thymidine reversal. Increasing concentrations of ara-A (Fig. 1 B-D) produced increasing temporal delays in the maximal rate of DNA synthesis. The net synthesis of cellular DNA in the presence of 3.2 ,ug of ara-A per ml (Fig. 1B) Fig. 3 represents the net amount of trichloroacetic acidinsoluble radioactivity recovered from the peak representing viral DNA in a CsCl density gradient. In the absence of drug, the rate of viral DNA synthesis increased rapidly, with a maximum at approximately 2.5 h. Little or no synthesis of viral DNA occurred after 10 h. In the presence of 3.2 ,ug of ara-A per ml (Fig.  3B) , net synthesis of viral DNA was reduced 74%. Higher levels of ara-A (Fig. 3C,D) DNA synthesis. In contrast to the results seen with ara-A (Fig. 2) , ara-H did not induce a temporal delay in the maximal rate of DNA synthesis (Fig. 4) . Net host DNA synthesis in the presence of the highest dose of ara-H used, 32 pg/ml, was approximately 60% of the control value. Thus ara-H inhibited DNA synthesis to a slightly lesser extent than ara-A. Data from other experiments (results not shown) have confirmed that ara-H inhibited cellular DNA synthesis to a lesser but significantly different degree than ara-A.
Inhibition of viral DNA synthesis by ara-H. Figure 5 illustrates the inhibition by ara-H of HSV DNA synthesis in infected KB cells.
Whereas doses of >10 mg of ara-A per ml virtually abolished viral DNA synthesis, ara-H was less effective as an inhibitor of viral DNA synthesis, producing a 49% inhibition at 3.2 pg/ml, a 69% inhibition at 10 pg/ml, and a 91% inhibition at 32 ,ug/ml. Thus ara-H can be seen to selectively inhibit viral DNA but to a lesser extent than ara-A. 
DISCUSSION
When compared in their ability to reduce syncytia formation by HSV, ara-A was approximately 10 times more active than its deaminated catabolite ara-H. These results are consistent with those published earlier by Miller and co-workers (18) . The inhibitory action of ara-A was optimal when added before or during viral DNA synthesis. The drug was markedly less active when added at times greater than 6 h postinfection.
There is a preponderance of evidence indicating cell fusion as the principal means by which macroscopic syncytia are formed (23) . Inhibition of DNA-dependent ribonucleic acid synthesis by ANTIVIRAL ACTIVITY OF ARA-A AND ARA-H 125 actinomycin C (9) or inhibition of protein synthesis by cycloheximide (8) prevents HSV-induced polykarocyte formation. In contrast, inhibition of viral DNA synthesis by halogenated pyrimidines (see, for example, ref. 29) does not affect syncytium formation although the production of infectious virions may be completely suppressed. Thus, one may infer that cell fusion is dependent upon early transcription and translation but not upon reduplication of the viral genome of HSV. Arabinosyladenine and arabinosylhypoxanthine appear to function in reducing the number of apparent plaques in an assay not by blocking initial polykaryocyte formation but rather by limiting the size of the resulting syncytium. Observations in our laboratory by means of phase microscopy of drug-treated HSV-infected cells support this hypothesis.
As a means of further studying the antiviral activity of ara-A and ara-H, the synchronized KB cell suspension system of Bello (3) and of Cohen et al. (6) was modified for use. It was anticipated that this system would not only offer the convenience of working with suspension cultures but would also enable us to study the inhibitory effects of the drugs on DNA synthesis during the synthetic (S) phase of the cell cycle.
Virus replication was measured by assaying cell-associated and free virus from drugtreated, infected, synchronized cultures. As reflected in Fig. 1 , ara-A was seen to depress peak virus production at an efficiency some 8 to 10 times greater than that observed with ara-H. Preliminary observations in the electron microscope (results not shown) indicate that although there is a dose-dependent decrease in the number of PFU, the total number of apparently normal virions remains relatively constant when the drug-treated infected cells are compared with the nontreated infected cells. This would suggest that the physical particle/PFU ratio is increasing with drug treatment. This hypothesis is currently being explored in our laboratory and will be the subject of a future commumcation.
Rates of both cellular and viral DNA synthesis were studied in infected and noninfected drug-treated synchronized cells. Unexpectedly, we observed that ara-A induced a temporal shift in the maximal rates of DNA synthesis in control cells. In contrast, ara-H produced only a small reduction in the net amount of DNA synthesized. A careful examination of Fig. 2 A selective inhibition ofcellular DNA synthesis in HSV-infected and Epstein-Barr virus-infected cells has been reported with cordycepin (1) and with hydroxyurea (12) .
The above studies suggest that the selective inhibition of the synthesis of HSV DNA by ara-A and ara-H is most probably due to the preferential inhibition of a step in nucleotide metabolism catalyzed by a virus-specified enzyme. have not been encouraging in crude systems (4; C. Reinke and C. Shipman, unpublished observations), we feel confident that highly purified preparations of this or other virusspecified enzymes will support the hypothesis that arabinosyl nucleosides owe their selective action to the differential inhibition of virusinduced enzymes. A somewhat similar phenomenon was reported by Yoshikura (32) . Treatment of C3H2K cells arrested in Gl phase with arabinosylcytosine for 2 h caused a delay in DNA synthesis when the cells were subsequently induced to divide by medium change. In this experiment, however, it was the onset of the synthetic phase that was delayed. Once DNA synthesis was initiated, the rate appeared consistent with that observed in the control cells.
Both York and LePage (31) and Moore and Cohen (19) have shown that the triphosphate of ara-A (ara-ATP) inhibits ribonucleoside diphosphate reductase in ascitic TA3 and Novikoff hepatoma cells. The Ki of ara-ATP for inhibition of this enzyme was found to be 30 to 110 ,uM. Although this Ki is considerably greater than the 1 uM Ki of ara-ATP for DNA polymerase (11), it is possible that even low concentrations of ara-A may inhibit DNA synthesis in cells that are synchronized by means of a thymidine-induced blockade of ribonucleotide reductase. This hypothesis is directly amenable to experimental exploration by studying the effects of ara-A on DNA synthesis in cells synchronized by means other than a blockage of the reductase enzyme system.
The mechanism by which ara-H acts in inhibiting host DNA synthesis may be very different from that of ara-A. Unfortunately, studies dealing with the inhibition of DNA polymerase or ribonucleoside diphosphate reductase by the triphosphate of ara-H are lacking in the published literature.
The process by which arabinosyladenine and arabinosylhypoxanthine selectively inhibit the synthesis of viral DNA is currently unknown.
Studies with asynchronous suspension and monolayer cultures of KB cells (P. M. Schwartz, C. Shipman, Jr., and J. C. Drach, submitted for publication) confirm the selective effect of these nucleoside antibiotics, and the trivial explanation that the selectivity is dependent upon the cell system used can be rejected.
